Subscribe to: Heart Care Info RSS Feed  

Heart Care Info - Heart Disease Prevention & Treatment

  Heart health     Cardiopathy     Heart study     Cardiology      Email A Friend  
Heart disease
Heart attack
Heart failure
Heart surgery
Heart Care Info
Heart transplantation
Bypass surgery
Cardiovascular disease
Arrhythmia
Atherosclerosis
Heart rate
Cardiac arrest
Cardiac death
Cardiac surgery
Cardiovascular system
Cardiomyopathy
Endocarditis
Cardiomegaly
Myocarditis


Absence of thrombospondin 2 increases cardiomyocyte damage and matrix disruption in doxorubicin induced cardiomyopathy, cardiomyopathy

Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.


Heart Care Guide - http://www.heartcareguide.net

GC van Almen, M Swinnen, P Carai... - Journal of molecular ..., 2011 - Clinical use of the antineoplastic agent doxorubicin (DOX) is limited by its cardiomyocyte toxicity. Attempts to decrease cardiomyocyte injury showed promising results in vitro, but failed to reduce the adverse effects of DOX in vivo, suggesting that other mechanisms ...

Clinical use of the antineoplastic agent doxorubicin (DOX) is limited by its cardiomyocyte toxicity. Attempts to decrease cardiomyocyte injury showed promising results in vitro, but failed to reduce the adverse effects of DOX in vivo, suggesting that other mechanisms contribute to its cardiotoxicity as well. Evidence that DOX also induces cardiac injury by compromising extracellular matrix integrity is lacking. The matricellular protein thrombospondin-2 (TSP-2) is known for its matrix-preserving function, and for modulating cellular function. Here, we investigated whether TSP-2 modulates the process of doxorubicin-induced cardiomyopathy (DOX-CMP). TSP-2-knockout (TSP-2-KO) and wild-type (WT) mice were treated with DOX (2 mg/kg/week) for 12 weeks to induce DOX-CMP. Mortality was significantly increased in TSP-2-KO compared to WT mice. Surviving DOX-treated TSP-2-KO mice had depressed cardiac function compared to WT animals, accompanied by increased cardiomyocyte apoptosis and matrix damage. Enhanced myocyte damage in the absence of TSP-2 was associated with impaired activation of the Akt signaling pathway in TSP-2-KO compared to WT. The absence of TSP-2, in vivo and in vitro, reduced Akt activation both under non-treated conditions and after DOX. Importantly, inhibition of Akt phosphorylation in cardiomyocytes significantly reduced TSP-2 expression, unveiling a unique feedback loop between Akt and TSP-2. Finally, enhanced matrix disruption in DOX-treated TSP-2-KO hearts went along with increased matrix metalloproteinase-2 levels. Taken together, this study is the first to provide evidence for the implication of the matrix element TSP-2 in protecting against DOX-induced cardiac injury and dysfunction.

More Details:

Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
Cardiovascular health
Cardiovascular surgery
Coronary artery disease
Coronary artery bypass graft

Subscribe to Heart Care Info by Email
Your email address:

Heart Care Guide
Life & Health Center
Find Doctor in Town
Health Care Jobs
Heart disease treatment